Literature DB >> 12748663

Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.

S Mori1, H El-Baki, C A Mullen.   

Abstract

In major histocompatibility complex (MHC)-matched allogeneic hematopoietic stem cell transplantation (HSCT), donor responses are directed against multiple host minor histocompatibility antigens (mHAgs), producing graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effects. We studied MHC-matched, mHAg-mismatched C3H.SW>C57BL/6 HSCT in which three mHAg are molecularly defined (B6dom1, H3, H13) to determine if there is a hierarchy of immunodominance among the mHAgs and to learn the contribution of each to GVHD. We found that B6dom1 was the immunodominant mHAg. B6dom1 did not block responses to the subdominant mHAgs H3 and H13. The mechanism of immunodominance was not mHAg avidity or affinity for class I. B6dom1 elicited a broader variety of Vbeta clonotypes than either H3 or H13. Severe GVHD could occur in the absence of a strong B6dom1 response. Alloreactivity to isolated B6dom1, H3 or H13 differences did not produce severe GVHD. We concluded that immunodominance is explained by both mHAg density on host cells and the repertoire of donor T cells capable of responding to the mHAgs. Clinically significant GVHD requires donor responses to multiple mHAgs. Modulation of responses to a single immunodominant mHAg is insufficient for the prevention of GVHD, while immunotherapies directed against isolated mHAgs may not provoke severe GVHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748663     DOI: 10.1038/sj.bmt.1704021

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.

Authors:  Johan Jansson; Yu-Chiao Hsu; Igor I Kuzin; Andrew Campbell; Craig A Mullen
Journal:  Leuk Res       Date:  2010-11-12       Impact factor: 3.156

2.  Evidence of B cell immune responses to acute lymphoblastic leukemia in murine allogeneic hematopoietic stem cell transplantation recipients treated with donor lymphocyte infusion and/or vaccination.

Authors:  Craig A Mullen; Andrew Campbell; Olena Tkachenko; Johan Jansson; Yu-Chiao Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-08       Impact factor: 5.742

3.  Primary vascularization of the graft determines the immunodominance of murine minor H antigens during organ transplantation.

Authors:  Jean Kwun; Subramaniam Malarkannan; William J Burlingham; Stuart J Knechtle
Journal:  J Immunol       Date:  2011-09-07       Impact factor: 5.422

4.  High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.

Authors:  Faith M Young; Andrew Campbell; Kris Lambert Emo; Johan Jansson; Pin-Yi Wang; Craig T Jordan; Craig A Mullen
Journal:  Biol Blood Marrow Transplant       Date:  2008-04-14       Impact factor: 5.742

5.  Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Scott S Graves; Maura H Parker; Rainer Storb
Journal:  ILAR J       Date:  2018-12-31

6.  Acute lymphoid leukemia cells with greater stem cell antigen-1 (Ly6a/Sca-1) expression exhibit higher levels of metalloproteinase activity and are more aggressive in vivo.

Authors:  Yu-Chiao Hsu; Kurt Mildenstein; Kordell Hunter; Olena Tkachenko; Craig A Mullen
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

7.  Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.

Authors:  Yang Jo Chung; Terry J Fry; Peter D Aplan
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.